🇺🇸 FDA

Intelligence · Clinical Pipeline

AstraZeneca Pipeline

All ClinicalTrials.gov programs at AstraZeneca — phase, modality, and trial IDs.

Programs
249

Quick answer

AstraZeneca has 249 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. TRUQAP 200 mg film-coated tablets, TRUQAP 160 mg film-coated tablets

    AstraZeneca AB

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  3. Tozorakimab-placebo, Tozorakimab, SALBUTAMOL

    AstraZeneca AB

    Asthma

    phase 2 small molecule active

    1 trial

  4. Tremelimumab placebo, concentrate for solution for infusion, Tremelimumab

    AstraZeneca AB

    unresectable pleural or peritoneal malignant mesothelioma

    phase 2 small molecule active

    1 trial

  5. Venclyxto 100 mg film-coated tablets, RITUXIMAB, Calquence 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, RITUXIMAB, Venclyxto 10 mg film-coated tablets

    AstraZeneca AB

    Treatment Naïve Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  6. Venclyxto 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets

    AstraZeneca AB

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    phase 2 small molecule active

    1 trial

  7. Zibotentan, DAPAGLIFLOZIN, Zibotentan placebo, Dapagliflozin placebo

    AstraZeneca AB

    Cirrhosis of the liver is a condition in which the liver is scarred and damaged

    phase 2 small molecule active

    1 trial

  8. 15O-WATER, Natriumklorid Fresenius Kabi, 9 mg/ml, infusionsvätska, lösning, AZD3427, Dopamin Fresenius 50 mg/5 ml, Konzentrat zur Herstellung einer Infusionslösung, Placebo for AZD3427 or AZD3427 diluent

    AstraZeneca AB

    Heart failure with reduced ejection fraction, Renal impairment

    phase 1 small molecule active

    1 trial

  9. A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus

    AstraZeneca AB

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  10. A Phase 1 open-label positron emission tomography TRIAL to assess changes in liver uptake of [68Ga]Ga-FAPI-46 following oral administration of single doses of AZD2389 to patients with advanced liver fibrosis (PECHORA)

    AstraZeneca AB

    advanced liver fibrosis

    phase 1 other active

    1 trial

  11. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants with Established Atherosclerotic Cardiovascular and Chronic Kidney Disease

    AstraZeneca AB

    Chronic Kidney disease, Atherosclerotic Cardiovascular Disease

    phase 1 other active

    1 trial

  12. A Phase I, Randomised, Investigator- and Participant-blinded, Placebo-Controlled, Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants with Obesity.

    AstraZeneca AB

    Cardiorenal disease

    phase 1 other active

    1 trial

  13. A Phase I, Randomized, Partial Double-blind, Single dose, 3-Way Cross-over Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol for BGF MDI HFO Compared with BGF MDI HFA Using an AeroChamber Plus Flow-Vu Spacer and to Compare the Lung Exposure of BGF MDI HFO with a Spacer to BGF MDI HFO without a Spacer

    AstraZeneca AB

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  14. A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC

    AstraZeneca AB

    Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 1 other active

    1 trial

  15. A Phase Ib, Multicentre, Randomised, Single-blind, Parallel-group, Placebo-controlled, Study to Characterise the Pharmacokinetics and Pharmacodynamics of AZD4604 Administered via the Turbuhaler® Device in Adults with Mild Asthma

    AstraZeneca AB

    Asthma

    phase 1 other active

    1 trial

  16. A Single Dose, Non-randomised, Open-label, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants with Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants

    AstraZeneca AB

    Healthy Volunteers, Renal Impairment and End Stage Kidney Disease

    phase 1 other active

    1 trial

  17. A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adults with Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists

    AstraZeneca AB

    Asthma

    phase 1 other active

    1 trial

  18. A Study to Evaluate MEDI5752 in Subjects with Advanced Solid Tumors

    AstraZeneca AB

    Advanced solid tumours

    phase 1 other active

    1 trial

  19. A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab via Subcutaneous Administration in Healthy Volunteers

    AstraZeneca AB

    healthy volunteers

    phase 1 other active

    1 trial

  20. A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants with Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

    AstraZeneca AB

    Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies

    phase 1 other active

    1 trial

  21. A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants with Advanced Solid Tumors Previously Treated with Standard of Care Therapy

    AstraZeneca AB

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  22. A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants with Renal Impairment

    AstraZeneca AB

    Impaired renal function

    phase 1 other active

    1 trial

  23. A placebo-controlled safety and tolerability study of intravenous (IV) and subcutaneous (SC) AZD1163 in healthy volunteers

    AstraZeneca AB

    Rheumatoid Arthritis

    phase 1 other active

    1 trial

  24. A study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of surovatamig in adult participants with rheumatoid arthritis or systemic lupus erythematosus.

    AstraZeneca AB

    Systemic Lupus Erythematosus, Rheumatoid Arthritis

    phase 1 other active

    1 trial

  25. A study to investigate the effect of capivasertib on the pharmacokinetics of oral dextromethorphan (CYP2D6) in healthy participants

    AstraZeneca AB

    Healthy participants

    phase 1 other active

    1 trial

  26. A study to investigate the effect of oral ticagrelor on the pharmacokinetics of oral rosuvastatin when given in healthy participants

    AstraZeneca AB

    Clinical trial healthy volunteer

    phase 1 other active

    1 trial

  27. A study to investigate the safety and tolerability of Trastuzumab Deruxtecan in combination with Immunotherapy Agents with and without chemotherapy, as the first treatment option for patients with advanced HER2 over-expressing Non-Small Cell Lung Cancer.

    AstraZeneca AB

    Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (OE)

    phase 1 other active

    1 trial

  28. A trial to learn about how multiple doses of itraconazole change how AZD5004 moves throughout the body over time in healthy adults and how multiple doses of AZD5004 change how ethinyl estradiol and levonorgestrel move throughout the body overtime in healthy female adults

    AstraZeneca AB

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  29. A trial to learn how baxdrostat affects the heartbeat in healthy participants

    AstraZeneca AB

    Treatment-resistant hypertension, Primary aldosteronism, Uncontrolled hypertension

    phase 1 other active

    1 trial

  30. A trial to learn how ceralasertib affects the way certain medications move throughout the body over time and how safe it is to use ceralasertib with these medications in adults with advanced solid tumors

    AstraZeneca AB

    Advanced solid tumour

    phase 1 other active

    1 trial

  31. A trial to learn how much [11C]savolitinib enters the brains of healthy participants

    AstraZeneca AB

    Healthy Volunteers

    phase 1 other active

    1 trial

  32. A trial to learn how much budesonide, glycopyrronium, and formoterol fumarate (BGF) gets into and moves throughout the body when it is taken with hydrofluoroolefin (HFO) compared to when it is taken with hydrofluoroalkane (HFA) in healthy adults

    AstraZeneca AB

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  33. A trial to learn how safe AZD4063 is, how it moves throughout the body over time, and how it affects the levels of PLN mRNA in adults with dilated cardiomyopathy because of an R14del mutation in the PLN gene

    AstraZeneca AB

    PLN R14del Dilated Cardiomyopathy

    phase 1 other active

    1 trial

  34. A trial to learn how safe AZD5335 is and if a drug called itraconazole changes how AZD5335 moves through the body over time in adults with ovarian, peritoneal, or fallopian tube cancer

    AstraZeneca AB

    Ovarian cancer Primary peritoneal cancer Fallopian tube cancer

    phase 1 other active

    1 trial

  35. A trial to learn how saruparib works and how safe it is in the bodies of adults with advanced solid tumors

    AstraZeneca AB

    advanced solid malignancies

    phase 1 other active

    1 trial

  36. A trial to learn how well different doses of andexanet alfa work and how they affect blood clotting throughout the body in healthy adults who have taken an FXa inhibitor

    AstraZeneca AB

    Healthy Volunteers

    phase 1 other active

    1 trial

  37. A trial to learn if AZD5335 alone and in combination with other treatments is safe and effective and how it moves through the body in people with solid tumors

    AstraZeneca AB

    Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive recurrent (PSR) ovarian cancer, Lung Adenocarcinoma, and endometrial cancer.

    phase 1 other active

    1 trial

  38. A trial to learn if AZD9829 is safe and works alone and in combination with other treatments for participants with certain blood cancers.

    AstraZeneca AB

    CD123-Positive Hematological Malignancies: Module 1 focuses on R/R Acute Myeloid Leukemia and R/R Myelodysplastic Syndrome.

    phase 1 other active

    1 trial

  39. A trial to learn if itraconazole and carbamazepine affect how AZD5462 moves throughout the bodies of healthy adults

    AstraZeneca AB

    Chronic Heart Failure

    phase 1 other active

    1 trial

  40. AZD5492

    AstraZeneca AB

    B-Cell Malignancies

    phase 1 small molecule active

    1 trial

  41. An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab

    AstraZeneca AB

    Inflammation, Respiratory

    phase 1 other active

    1 trial

  42. An Open-label, Single-group, Three-period, Fixed-sequence, Phase I Study to Assess the Pharmacokinetics of AZD6793 Tablets When Administered Alone and in Combination with Itraconazole Capsules in Healthy Adult Female and Male Participants

    AstraZeneca AB

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  43. An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients

    AstraZeneca AB

    Breast Cancer

    phase 1 other active

    1 trial

  44. Ceralasertib, IMFINZI 50 mg/mL concentrate for solution for infusion, INFLIXIMAB, MYCOPHENOLATE MOFETIL, AZD4773, IMJUDO 20 mg/ml concentrate for solution for infusion.

    AstraZeneca AB

    • Non-small cell lung cancer (Stage III, unresectable) • Small cell lung cancer (Limited stage) • Hepatocellular carcinoma (Unresectable) • Advanced or Metastatic non-small cell lung cancer

    phase 1 small molecule active

    1 trial

  45. DEXTROMETHORPHANE ELERTE 1,5 mg/ml, sirop, AZD3470, AZD3470, Midazolam-ratiopharm® 2 mg/ml orale Lösung

    AstraZeneca AB

    Advanced/metastatic solid tumors that are MTAP deficient.

    phase 1 small molecule active

    1 trial

  46. Koselugo 25 mg hard capsules, Koselugo 10 mg hard capsules

    AstraZeneca AB

    Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)

    phase 1 small molecule active

    1 trial

  47. LENVIMA 4 mg hard capsules, volrustomig, Kisplyx 10 mg hard capsules, Kisplyx 4 mg hard capsules, LENVIMA 10 mg hard capsules

    AstraZeneca AB

    Advanced Renal Cell Carcinoma

    phase 1 small molecule active

    1 trial

  48. Lynparza 100 mg film-coated tablets, AZD2281, AZD2281, AZD2281

    AstraZeneca AB

    solid tumors

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does AstraZeneca have?

249 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.